Clinical characteristics and outcomes of ocular allergy in Thai children
Rasamee Jongvanitpak,1 Pakit Vichyanond,1 Orathai Jirapongsananuruk,1 Nualanong Visitsunthorn,1 Punchama Pacharn1
1 Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Abstract
Background: Allergic conjunctivitis (AC) is the most common ocular condition in allergic children. In tropical countries, the study about the clinical features and outcome of treatment is very limited.
Objective: To review clinical characteristics and outcomes of treatment in children with ocular allergy.
Methods: Children with history of AC were classified to seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC). The clinical history and outcome of treatment were recorded.
Results: One hundred and sixty-four children were recruited. PAC was the most common type (61.6%), followed by SAC (21.3%), VKC (12.2%), and AKC (4.9%). Male preponderance was found in all groups. Mean age of onset was 6.8 ± 2.8 years. Allergic rhinitis was the most common co-morbidity (97.6%). The common sensitized allergen is house-dust mites (86.1%). Standard treatments in all groups were natural tear and topical olopatadine. Add-on medications were usually needed in severe types of AC (VKC, AKC). History of topical corticosteroid use was 68.8% and 12.5% in VKC and AKC, respectively. All of them can discontinue topical corticosteroid when topical tacrolimus was applied. The overall remission was found 35% in VKC group and 63% in AKC group. The median duration of treatment was 20.5 months in VKC group and 11 months in AKC group.
Conclusion: most Thai children with AC sensitized to house-dust mites. In severe forms of AC, most patients needed add-on medication. The use of topical calcineurin inhibitor as an add-on therapy can decrease the use of topical corticosteroid.
Key words: conjunctivitis, allergic conjunctivitis, keratoconjunctivitis, treatment outcome, tacrolimus,